Juliette Berangere Audet Acquires 1,104 Shares of NewAmsterdam Pharma (NASDAQ:NAMS) Stock

NewAmsterdam Pharma (NASDAQ:NAMS) insider Juliette Berangere Audet bought 1,104 shares of the stock in a transaction on Thursday, September 26th. The shares were bought at an average cost of $15.70 per share, with a total value of $17,332.80. Following the purchase, the insider now owns 1,104 shares of the company’s stock, valued at $17,332.80. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

NewAmsterdam Pharma Trading Up 4.2 %

Shares of NewAmsterdam Pharma stock opened at $17.29 on Wednesday. NewAmsterdam Pharma has a 52-week low of $5.63 and a 52-week high of $26.35. The company has a 50 day moving average of $16.50 and a 200 day moving average of $18.92.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.51) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.08. The company had revenue of $2.28 million for the quarter, compared to analyst estimates of $2.20 million. On average, research analysts predict that NewAmsterdam Pharma will post -2.06 EPS for the current fiscal year.

Institutional Trading of NewAmsterdam Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NAMS. Parkman Healthcare Partners LLC increased its holdings in shares of NewAmsterdam Pharma by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 300,750 shares of the company’s stock valued at $3,359,000 after acquiring an additional 51,726 shares during the period. Opaleye Management Inc. acquired a new position in shares of NewAmsterdam Pharma in the 4th quarter valued at $2,964,000. Yarbrough Capital LLC acquired a new position in shares of NewAmsterdam Pharma in the 1st quarter valued at $567,000. Jennison Associates LLC acquired a new position in shares of NewAmsterdam Pharma in the 1st quarter valued at $22,015,000. Finally, TimesSquare Capital Management LLC purchased a new position in NewAmsterdam Pharma in the 1st quarter valued at $5,407,000. Institutional investors and hedge funds own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Needham & Company LLC assumed coverage on shares of NewAmsterdam Pharma in a research note on Wednesday, August 28th. They issued a “buy” rating and a $36.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $31.00 price objective on shares of NewAmsterdam Pharma in a research note on Thursday, September 5th. Finally, Piper Sandler reissued an “overweight” rating and issued a $37.00 price objective on shares of NewAmsterdam Pharma in a research note on Monday, September 23rd. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $33.80.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.